Voreloxin

Catalog No. :
ACMMLB045
CAS No. :
175414-77-4
Molecular Formula :
C18H19N5O4S
Molecular Weight :
401.45

IUPAC Name:7-((3S,4S)-3-methoxy-4-(methylamino)pyrrolidin-1-yl)-4-oxo-1-(thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid

Voreloxin structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1mg95%$71.00Login to see priceInquiryInquiry
5mg95%$195.00Login to see priceInquiryInquiry
10mg95%$312.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameVoreloxin
IUPAC Name7-((3S,4S)-3-methoxy-4-(methylamino)pyrrolidin-1-yl)-4-oxo-1-(thiazol-2-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
MDL No.MFCD13185156
Molecular FormulaC18H19N5O4S
Molecular Weight401.45
SMILESO=C(C1=CN(C2=NC=CS2)C3=C(C=CC(N4C[C@H](OC)[C@@H](NC)C4)=N3)C1=O)O
InChI KeyXZAFZXJXZHRNAQ-STQMWFEESA-N
Synonym1,8-Naphthyridine-3-carboxylic acid, 1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)- | Q18395775 | SNS 595 | VOSAROXIN [INN] | 1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, 1,4-DIHYDRO-7-((3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-
CAS No.175414-77-4
PubChem CID9952884

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACMMLB045 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACMMLB045 route product structure diagram
    ACMMLB045175414-77-4
Inquiry

2. ACMMLB045 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACVUDT419 route compound structure diagram
    ACVUDT419372482-03-6 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACMMLB045 route product structure diagram
    ACMMLB045175414-77-4
Inquiry

Comments (0)